A Phase I/IB Study fo AZD2171 and Temsirolimus in Patients With Advanced Gynecological Malignancies.
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 01 Aug 2018
At a glance
- Drugs Cediranib (Primary) ; Temsirolimus (Primary)
- Indications Cervical cancer; Endometrial cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions
- 26 Jul 2018 Planned End Date changed from 1 Apr 2018 to 1 Dec 2018.
- 04 May 2017 Planned End Date changed from 1 Sep 2013 to 1 Apr 2018.
- 26 Aug 2013 Planned End Date changed from 1 Feb 2012 to 1 Sep 2013 as reported by ClinicalTrials.gov.